STOCK TITAN
  1. Home
  2. News
  3. ALEC

Alector - ALEC STOCK NEWS

Welcome to our dedicated page for Alector news (Ticker: ALEC), a resource for investors and traders seeking the latest updates and insights on Alector stock.

Alector, Inc. (ALEC) is a clinical-stage biotechnology leader pioneering immuno-neurology therapies targeting Alzheimer’s, Parkinson’s, and related neurodegenerative diseases. This page serves as the definitive source for official company announcements, research breakthroughs, and partnership developments.

Investors and researchers will find curated updates on clinical trial progress, regulatory milestones, and scientific publications. Our aggregation includes press releases about therapeutic candidates like AL001 (TREM2 agonist) and AL002, plus updates on the proprietary ABC platform enhancing drug delivery.

Key content categories cover phase trial results, collaboration agreements with major biopharma partners, and peer-reviewed study data. All materials are sourced directly from Alector’s communications to ensure accuracy and timeliness.

Bookmark this page for streamlined access to Alector’s latest developments in immune system modulation for brain health. Check regularly for updates on their innovative approach to combating neurodegeneration through validated genetic targets and advanced therapeutic engineering.

News

Alector to Participate in Upcoming Healthcare Conferences

Rhea-AI Summary
Alector, Inc. (ALEC) to participate in multiple investor conferences to discuss immuno-neurology advancements. Webcasts available on their website for 90 days post-event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.29%
Tags
conferences
-
News

Alector Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Rhea-AI Summary
Alector, Inc. (Nasdaq: ALEC) reported fourth quarter and full year 2023 financial results, highlighting achievements in clinical trials and breakthrough therapy designations. With $620.0 million in cash after an equity offering in January 2024, the company expects a cash runway through 2026. Recent developments include dosing the first participant in the PROGRESS-AD Phase 2 trial and achieving target enrollment in the pivotal INFRONT-3 Phase 3 trial.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.29%
Tags
earnings
-
News

Alector to Host Fourth Quarter and Full-Year 2023 Earnings Call

Rhea-AI Summary
Alector, Inc. (Nasdaq: ALEC) will host a conference call on February 27, 2024, to discuss fourth-quarter results and provide a full-year business update. The event will be webcast live on their website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.05%
Tags
conferences earnings
News

Alector Announces First Patient Dosed in PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Patients with Early Alzheimer’s Disease

Rhea-AI Summary
Alector, Inc. and GSK plc announced the dosing of the first patient in the global Phase 2 clinical trial of AL101/GSK4527226, an investigational human monoclonal antibody for early Alzheimer’s disease. The trial aims to enroll approximately 282 patients and is a randomized, double-blind, placebo-controlled study to assess the safety and efficacy of two dose levels of AL101 compared to placebo. AL101 has been shown to be generally well tolerated and increased progranulin levels in healthy volunteers. The primary endpoint of the study is disease progression as measured by the Clinical Dementia Rating Sum of Boxes (CDR®-SB).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.34%
Tags
clinical trial
-
News

FDA Grants Latozinemab Breakthrough Therapy Designation for Frontotemporal Dementia Due to a Progranulin Gene Mutation (FTD-GRN)

Rhea-AI Summary
Alector, Inc. and GSK plc announced that the U.S. FDA has granted Breakthrough Therapy Designation to latozinemab, an investigational medicine for the treatment of frontotemporal dementia with a progranulin gene mutation (FTD-GRN). This designation is based on data from the INVOKE-2 Phase 2 clinical trial, and latozinemab is currently being studied in the pivotal INFRONT-3 Phase 3 study. The FDA's Breakthrough Therapy Designation is intended to expedite the development and review of drugs for serious conditions with preliminary clinical evidence indicating substantial improvement over available therapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.96%
Tags
none
-
News

Alector Announces Closing of Public Offering

Rhea-AI Summary
Alector, Inc. announced the closing of its underwritten public offering of shares of its common stock, selling 10,869,566 shares and granting the underwriter a 30-day option to purchase up to an additional 1,630,434 shares. The gross proceeds to Alector from the offering are approximately $75 million. Cantor Fitzgerald & Co. acted as the sole book-running manager for the offering. The offering was made pursuant to a shelf registration statement on Form S-3 that was previously filed with and subsequently declared effective by the SEC. This press release does not constitute an offer to sell or a solicitation of an offer to buy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.91%
Tags
offering
News

Alector Announces Pricing of Public Offering of Common Stock

Rhea-AI Summary
Alector, Inc. (Nasdaq: ALEC) announced the pricing of an underwritten public offering of 10,869,566 shares of its common stock for total gross proceeds of $75 million. The offering is expected to close on January 19, 2024. Cantor Fitzgerald & Co. is acting as sole book-running manager for the offering. The offering is made pursuant to a shelf registration statement on Form S-3 that was previously filed with and subsequently declared effective by the SEC. This press release shall not constitute an offer to sell or a solicitation of an offer to buy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.01%
Tags
offering
-
News

Alector Announces Proposed Public Offering of Common Stock

Rhea-AI Summary
Alector, Inc. announced its intention to offer shares of its common stock in an underwritten public offering, with the underwriter having a 30-day option to purchase additional shares. The offering is being made pursuant to a shelf registration statement previously filed with the SEC. Cantor Fitzgerald & Co. is acting as the sole book-running manager for the proposed offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.01%
Tags
offering
-
News

Alector to Host Two Virtual Research and Development Events Highlighting TREM2 and Progranulin Programs

Rhea-AI Summary
Alector, Inc. (ALEC) to host virtual events in December to discuss TREM2 and progranulin (PGRN) programs with leading scientific and clinical experts. The events will cover the potential as a therapeutic target for Alzheimer’s Disease and a pivotal stage program for Frontotemporal Dementia with additional opportunities including Alzheimer’s Disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.03%
Tags
conferences
News

Alector to Participate in the Stifel Healthcare Conference

Rhea-AI Summary
Alector, Inc. (Nasdaq: ALEC) to participate in fireside chat at Stifel Healthcare Conference on November 14, 2023. Live webcast and replay available on company website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.3%
Tags
conferences
Stock ALEC logo
Alector

Nasdaq:ALEC

ALEC Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

ALEC Stock Data

91.17M
85.85M
13.37%
83.09%
5.57%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
SOUTH SAN FRANCISCO